Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that lower serum and tissue vitamin D receptor levels in alopecia areata and androgenetic alopecia patients may play a role in the pathogenesis of these hair diseases.

In this study, topical methyl vanillate application increased hair count and hair mass index in women with androgenetic alopecia by enhancing WNT10B expression, suggesting a potential new treatment strategy.

This study found that early onset androgenetic alopecia in young Asian Indian Gujarati men is independently associated with an increased risk of coronary artery disease.

This study found that among Korean men with AGA, drinking and smoking were associated with greater hair loss severity, while family history was linked to more severe hair loss and earlier onset.

This study found that the occipital scalp is significantly involved in female pattern hair loss, with some patients showing clinically visible alopecia.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This study found that in women with androgenetic alopecia, hair density is lower, and thin and non-growing hair are more common on the midscalp compared to the occiput.

This study investigated a new formula called SV-loaded nanospanlastics for topical application to treat androgenic alopecia. It showed similar effectiveness to minoxidil lotion but with fewer adverse effects when used to enhance dermal delivery and efficacy of sodium valproate.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

This study found that 5% primed conditioned medium from human umbilical cord blood-derived mesenchymal stromal cells significantly improved hair density, thickness, and growth rate in patients with androgenetic alopecia.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This study concluded that platelet-rich plasma injections significantly improved hair density, thickness, and scalp inflammation in both male and female pattern hair loss, with better outcomes in lower-grade cases.

In this study, the researchers observed that subjects with alopecia areata had the highest plasma level of cardiac troponin I, followed by those with androgenetic alopecia, and the lowest levels in individuals without hair loss.

This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

This study found that Sargassum muticum extract and apo-9′-fucoxanthinone promoted hair growth in rat and mouse models by increasing dermal papilla cell proliferation and activating certain signaling pathways.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.

This study found that patients with alopecia areata exhibit a stronger deficiency in coping with stress compared to those with androgenetic alopecia and controls, suggesting a psychosomatic component to the condition.

This review discusses advancements in the genetic understanding of androgenic alopecia and the FDA-approved treatments, including a new laser hair comb, but reports no clinical results.

In this study, researchers observed that in advanced androgenetic alopecia, increased DNA damage in the frontal bald area may lead to cell apoptosis due to impaired repair capacity.

This study found significant differences in bcl-2 expression between areas of the scalp affected and unaffected by androgenetic alopecia, suggesting a uniform follicle population or synchronized follicular cycling in affected areas.

This study observed that patients with alopecia areata often have a T-cell receptor repertoire in skin lesions that suggests a specific antigen-driven immune response may be important in the disease's pathogenesis.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This study found that dermal papilla cells from balding follicles exhibit distinct growth characteristics compared to non-balding cells, suggesting their potential as a model for understanding androgenetic alopecia.

This study found that Physcion from Polygonum multiflorum may be an effective natural 5α-reductase inhibitor for treating androgenic alopecia by enhancing hair growth and improving follicle morphology in laboratory settings.

This study found that PRP therapy resulted in better hair growth and patient satisfaction than minoxidil therapy in men with androgenetic alopecia over six months, and patients with higher platelet counts in PRP experienced greater improvement.